Hot Investor Mandate: Newly Founded Angel Group Looks to Invest in Early-Stage Medical Device and Digital Health Companies in the US

11 Feb

A newly established angel investor group headquartered in the US with ties/members in China is looking for innovative opportunities in the healthcare sector. The firm invest in early stages, including seed and series A, The firm’s typical check size ranges from $100K – $500K. The firm is open to USA based companies. 
 
The firm is primarily focused on investing in digital health and medical devices. The firm is indication- and modality- agnostic. 
 
The firm is open to both co-investing and leading, though prefers to co-invest. The firm likes with see a management team from a relevant domain with previous business experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

RFK Jr. & Trump Think Govt. Grants are Broken. Are They? The Problem with Life Science Grant Funding

11 Feb

By Sougato Das, President and COO, Life Science Nation (LSN)

Sougato-DasThe hot topic is that government grants are fundamentally broken in Life Science. RFK Jr. is calling out NIH-funded studies as problematic and seeks to fix them by having Senate committees review proposals, restructuring and/or laying off NIH staff, and reducing infectious disease research while increasing chronic disease funding.

A 2023 study showed that nearly all FDA New Drug Applications from 2010 to 2019 relied on NIH funding in the early stages. Yet the biotech startup failure rate is 90%, according to Health Tech World and CBI Insights. So what is the disconnect, and what are the lessons Life Science Nation has learned from 12 years of helping startups get funded? One of the factors that can contribute to this failure rate: scientists and academics control the selection and evaluation process, and they often remain in the mix long after their expertise is most relevant. While they play a crucial role in assessing technical feasibility, when should they step aside when plotting the journey to commercialization?

The problem isn’t just that academic scientists struggle with translating discoveries into commercial products – such as navigating the FDA, clinical trials, and regulatory approvals – but that grant programs themselves fail to address the fundamentals essential for success. Instead of equipping grantees with the real-world skills needed for sales, business development, and strategic partnering, the “commercialization training” typically amounts to little more than teaching them how to prepare for a partnering event and deliver a 30-minute pitch deck.

This is the equivalent of bringing a knife to a gunfight. Securing funding and forming industry partnerships requires far more than a polished presentation. It demands a deep understanding of market positioning, deal structuring, sales strategy, and long-term capital planning – areas where most scientific founders are left unprepared. Until grant programs integrate commercialization expertise and ensure leadership transitions to business professionals at the right stage, billions in non-dilutive funding will continue to be wasted on technologies that never reach patients.

Innovative funding strategies that bridge the gap between academic research and commercial viability should be explored. Additionally, creating a supportive ecosystem that connects scientists with investors, industry partners, and mentors with funding and partnering expertise is crucial to guiding them through the commercialization process.

Meet Global Investors at RESI Europe in Barcelona! 

11 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation’s (LSN) is bringing RESI back to Barcelona on Monday, April 1, at the InterContinental Hotel. Co-organized with Biocat, RESI Europe will feature an in-person conference followed by two days of virtual partnering on April 2-3. The event will include Investor Panels, the Innovator’s Pitch Challenge, and Entrepreneur Workshops led by industry experts. One-on-one partnering meetings will be available throughout all three days, providing valuable opportunities to connect.

RESI Europe will welcome investors from venture capital firms, big pharma, private equity, angel groups, family offices, and more. Investors invited and registered have been vetted by LSN’s investor research team to ensure alignment with the fundraising companies in attendance. The RESI Partnering Platform allows participants to efficiently match with the most relevant contacts, creating meaningful opportunities to build relationships and advance business goals.

With its global reach, RESI provides a premier platform for life science companies and investors to connect, whether in Barcelona or at upcoming RESI conferences. Take a look at some of the investors registered for RESI Europe, and make sure to register now for a chance to meet with them!

Rhythm Biotherapeutics: Innovator’s Pitch Challenge Winner Spotlight

11 Feb

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiRhythm Biotherapeutics is a pioneering biotech company addressing a critical healthcare challenge with a unique approach. In this interview, Founder and CEO Darryl Davis shares insights into the company’s mission, recent milestones, and future goals.

He also discusses his experience participating in the Innovator’s Pitch Challenge at RESI JPM, how it has influenced his fundraising journey, and the role of Canadian life science startups on the global stage.

Learn more about Rhythm Biotherapeutics and its path forward.

Hot Investor Mandate: Investment Arm of Global Asset Management Firm Invests Up to $20M in Medical Device and Digital Health Companies, Focusing on US and Europe

4 Feb

A healthcare investment arm of a multi-strategy asset management firm focuses on early-stage opportunities in the medical device and digital health sectors, having invested approximately $250M USD in healthcare and medtech. The firm typically engages in Series A rounds and beyond, with check sizes ranging from $5M to $20M USD, and follow-on investments are a possibility. While the firm primarily focuses on the US (especially the Bay Area) and Europe, it remains open to global opportunities. 
 
The firm primarily considers opportunities in medical devices and digital health. Traditional asset-driven therapeutics are out of scope. The firm is agnostic to subsectors and indications but prefers disease areas with large addressable markets and companies with a clear reimbursement strategy. Some areas of interest include cardiovascular, ophthalmology, and diabetes. The fund typically evaluates clinical-stage opportunities but is open to considering design-stage companies, provided they have strong validation. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers founders with experience or a successful track record. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: VC Firm With Close Ties to Health Insurance Provider Seeks Investments in Devices, Diagnostics, Digital Health, and Healthcare Services

4 Feb

An investment firm manages funds for a major health insurance company in the US. The firm seeks to invest in healthcare companies of strategic interest to this insurance company while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in insurtech companies. The firm partners with payers and providers to drive innovation in healthcare, with a focus in medical devices, diagnostics, and AI solutions for providers. 
 
Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices. 
 
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Fund Invests in Seed to Series A Companies in Deeptech and CNS/Neuro Tech Across All Life Science Sectors

4 Feb

An early stage VC fund based in the US currently has $250M under management. The group focuses on highly technical, very early stage companies. The typical investment size is between $1M to $2M and they’re open to lead, co-lead and follow. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 

The firm have been highly active in deep tech/ R&D intensive investments, and have a significant biotech portfolio of notable/renowned companies in the industry. 
 
Currently, the firm’s team is focusing on Neuroscience and brain tech, like Neuromodulation, BCI, precision neuroscience, and infra from data driven angles, like AI in drug development, Multi Omics, from Seed to Series A. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

← Older Entries
Newer Entries →